Quantitative assessment of ALZ-50 immunoreactivity in Alzheimer's disease.
A quantitative assay for ALZ-50 immunoreactivity was evaluated in samples of superior temporal gyrus taken at autopsy from 13 Alzheimer patients and 11 controls. The assayable immunoreactivity appears to be stable for at least 24 hours postmortem but was lost with formalin fixation. The mean value of the Alzheimer patients was tenfold higher than that of the controls (P less than .002). The values of four Alzheimer samples overlapped with the low levels seen in controls, but no controls had elevated levels. In this sample population, therefore, the assay had a sensitivity of 69% and specificity of 100%.
Hyman
B T
BT
Neurology Service, Massachusetts General Hospital, Boston 02114.
Flory
J E
JE
Arnold
S E
SE
Van Hoesen
G W
GW
Schelper
R L
RL
Ghanbari
H
H
Haigler
H
H
D000368:Aged; D000544:Alzheimer Disease / Q000473:pathology*; D000941:Antigens / Q000032:analysis*; D001921:Brain / Q000473:pathology*; D003937:Diagnosis, Differential; D006801:Humans; D007124:Immunoenzyme Techniques; D009454:Neurofibrils / Q000473:pathology; D009474:Neurons / Q000473:pathology; D013702:Temporal Lobe / Q000473:pathology
C056167:Alzheimer's disease antigen; D000941:Antigens